Resectable pancreatic cancer: The role for neoadjuvant/preoperative therapy

HPB

Volumn 8, Issue 5, 2006, Pages 365-368

  Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Neoadjuvant therapy; Pancreatic cancer; Pancreatic surgery whipple procedure; Preoperative therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEHYDRATION; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; METASTASIS; NAUSEA; OUTCOMES RESEARCH; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; REVIEW; VOMITING;

EID: 33749161234     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820600804005     Document Type: Review

References (11)

1. Breslin, TM and Hess, KR and Harbison, DB and Jean, ME and Cleary, KR and Dackiw, AP and (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration Ann Surg Oncol, 8, pp. 123-32.
2. Evans, DB and Rich, TA and Byrd, DR and Cleary, KR and Connelly, JH and Levin, B and (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg, 127, pp. 1335-9.
3. Greene, FL and Page, DL and Fleming, ID and Fritz, A and Balch, CM and Haller, DG and (2002) AJCC cancer staging manual 6th edn. New York: Springer-Verlag.
4. Pisters, PWT and Abbruzzese, JL and Janjan, NA and Cleary, KR and Charnsangavej, C and Crane, CN and (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma J Clin Oncol, 16, pp. 3843-50.
5. Pisters, PWT and Wolff, RA and Janjan, NA and (2002) Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome J Clin Oncol, 20, pp. 2537-44.
6. Pisters PWT, Wolff RA, Crane CH, Evans DB. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology 2005;19:393-404, 409; discussion 409-10, 412-16.
7. Raut, CP and Evans, DB and Crane, CH and Pisters, PWT and Wolff, RA. (2004) Neoadjuvant therapy for resectable pancreatic cancer Surg Oncol Clin N Am, 4, pp. 639-61.
8. Varadhachary, GR and Tamm, EP and Crane, C and Evans, DB and Wolff, RA. (2005) Borderline resectable pancreatic cancer Curr Treat Options Gastroenterol, 8, pp. 377-84.
9. Wolff, RA and Crane, CH and Li, D and Abbruzzese, JL and Evans, DB.(2006) Neoplasms of the exocrine pancreas. In Holland-Frei Cancer Medicine6th edn. (pp. 1331-58). Ontario: BC Decker.
10. Wolff, RA and Evans, DB and Gravel, DM and Lenzi, R and Pisters, PW and Lee, JE and (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma Clin Cancer Res, 7, pp. 2246-53.
11. VonHoff, DD and Evans, DB and Hruban, RH. (2005) Pancreatic Cancer. Sudbury MA: Jones and Bartlett.